Cannabinoid pharmacology: Implications for additional cannabinoid receptor subtypes

Chemistry and Physics of Lipids

Volumn 121, Issue 1-2, 2002, Pages 57-63

  Wiley, Jenny L ^a   Martin, Billy R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anandamide; Cannabinoid; Knockout mice; SR141716A; Vanilloid

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOL DERIVATIVE; RECEPTOR SUBTYPE; VANILLOID RECEPTOR;

CONFERENCE PAPER; DRUG BINDING; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MORPHOLINES; NAPHTHALENES; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

CANNABIS SATIVA;

EID: 0037207074     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-3084(02)00146-9     Document Type: Conference Paper

References (61)

1. Adams I.B., Ryan W., Singer M., Razdan R.K., Compton D.R., Martin B.R. Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci. 56:1995;2041-2048.
2. Adams I.B., Ryan W., Singer M., Thomas B.F., Compton D.R., Razdan R.K., Martin B.R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 273:1995;1172-1181.
3. Adams I.B., Compton D.R., Martin B.R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 284:1998;1209-1217.
4. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 38:1999;1083-1152.
5. Breivogel C.S., Griffin G., Di Marzo V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60:2001;155-163.
6. 9-THC in a drug-discrimination procedure. Exp. Clin. Psychopharmacol. 5:1997;195-202.
7. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 389:1997;816-824.
8. Compton D.R., Martin B.R. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J. Pharmacol. Exp. Ther. 283:1997;1138-1143.
9. 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 263:1992;1118-1126.
10. Compton D.R., Rice K.C., De Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., Martin B.R. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 265:1993;218-226.
11. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:1996;586-594.
12. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87.
13. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. 98:2001;9371-9376.
14. Devane W.A., Hanuš L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
15. Devane W.A., Dysarz F.A. III, Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
16. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Martin B.R. Cannabimimetic fatty acid derivatives: the anandamide family and other 'endocannabinoids'. Curr. Med. Chem. 6:1999;721-744.
17. Di Marzo V., Breivogel C., Bisogno T., Melck D., Patrick G., Tao Q., Szallasi A., Razdan R.K., Martin B.R. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. Eur. J. Pharmacol. 406:2000;363-374.
18. 2 receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75:2000;2434-2444.
19. 1 vanilloid receptor 'hybrid' ligands. Biochem. Biophys. Res. Commun. 281:2001;444-451.
20. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., Bisogno T. Anandamide receptors. Prostaglandins Leukotrienes Essent. Fatty Acids. 66:2002;377-391.
21. Di Marzo V., Griffin G., De Petrocellis L., Brandi I., Bisogno T., Williams W., Grier M.C., Kulasegram S., Mahadevan A., Razdan R.K., Martin B.R. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J. Pharmacol. Exp. Ther. 300:2002;984-991.
22. Felder C.C., Veluz J.S., Williams H.L., Briley E.M., Matsuda L.A. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol. Pharmacol. 42:1992;838-845.
23. Galiègue S., Mary S., Marchand J., Dussossoy D., Carrière D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:1995;54-61.
24. 35S]thio)-triphosphate binding assay in rat cerebellar membranes. J. Pharmacol. Exp. Ther. 285:1998;553-560.
25. Hájos N., Ledent C., Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience. 106:2001;1-4.
26. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. 87:1990;1932-1936.
27. Heyser C.J., Hampson R.E., Deadwyler S.A. Effects of delta-9 tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J. Pharmacol. Exp. Ther. 264:1993;294-307.
28. Hillard C.J., Harris R.A., Bloom A.S. Effects of the cannabinoids on physical properties of brain membranes and phospholipid vesicles: fluorescence studies. J. Pharmacol. Exp. Ther. 232:1985;579-588.
29. Houser S.J., Eads M., Embrey J.P., Welch S.P. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, delta(9)-THC and anandamide. Brain Res. 857:2000;337-342.
30. Howlett A.C., Champion T.M., Wilken G.H., Mechoulam R. Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology. 29:1990;161-165.
31. Járai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Razdan R.K., Zimmer A., Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. 96:1999;14136-14141.
32. Kaminski N.E. Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signalling cascade and altered gene expression. Biochem. Pharmacol. 52:1996;1133-1140.
33. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Bohme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 283:1999;401-404.
34. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40:1991;471-478.
35. Martin B.R., Beletskaya I., Patrick G., Jefferson R.G., Winckler R., Deutsch D.G., Di Marzo V., Dasse O., Mahadevan A., Razdan R.K. Cannabinoid properties of methylfluorophosphonate analogs. J. Pharmacol. Exp. Ther. 294:2000;1209-1218.
36. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
37. Monory K., Tzavara E.T., Lexime J., Ledent C., Parmentier M., Borsodi A., Hanoune J. Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem. Biophys. Res. Commun. 292:2002;231-235.
38. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-64.
39. Oh S.J., Ha H.J., Chi D.Y., Lee H.K. Serotonin receptor and transporter ligands - current status. Curr. Med. Chem. 8:2001;999-1034.
40. Pertwee R.G., Ross R.A. Cannabinoid receptors and their ligands. Prostaglandins Leukotrienes Essent. Fatty Acids. 66:2002;101-121.
41. Ryan W.J., Banner W.K., Wiley J.L., Martin B.R., Razdan R.K. Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain. J. Med. Chem. 40:1997;3617-3625.
42. Seltzman H.H., Fleming D.N., Thomas B.F., Gilliam A.F., McCallion D.S., Pertwee R.G., Compton D.R., Martin B.R. Synthesis and pharmacological comparison of dimethylheptyl and pentyl anandamide analogs. J. Med. Chem. 40:1997;3626-3634.
43. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., LeFur G., Caput D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270:1995;3726-3731.
44. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989-999.
45. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129:2000;227-230.
46. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
47. Tanda G., Munzar P., Goldberg S.R. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat. Neurosci. 3:2000;1073-1074.
48. Watanabe K., Narimatsu S., Matsunaga T., Yamamoto I., Yoshimura H. A cytochrome P450 isozyme having aldehyde oxygenase activity plays a major role in metabolizing cannabinoids by mouse hepatic microsomes. Biochem. Pharmacol. 46:1993;405-411.
49. Welch S.P., Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. 848:1999;183-190.
50. Welch S.P., Huffman J.W., Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J. Pharmacol. Exp. Ther. 286:1998;1301-1308.
51. Wiley J.L. Cannabis: discrimination of 'internal bliss'. Pharmacol. Biochem. Behav. 64:1999;257-260.
52. Wiley J.L., Balster R.L., Martin B.R. Discriminative stimulus effects of anandamide in rats. Eur. J. Pharmacol. 276:1995;49-54.
53. 9-tetrahydrocannabinol in rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 275:1995;1-6.
54. Wiley J.L., Golden K.M., Ryan W.J., Balster R.L., Razdan R.K., Martin B.R. Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys. Pharmacol. Biochem. Behav. 58:1997;1139-1143.
55. Wiley J.L., Compton D.R., Dai D., Lainton J.A.H., Phillips M., Huffman J.W., Martin B.R. Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J. Pharmacol. Exp. Ther. 285:1998;995-1004.
56. Wiley J.L., Ryan W.J., Razdan R.K., Martin B.R. Evaluation of cannabimimetic effects of structural analogs of anandamide in rats. Eur. J. Pharmacol. 355:1998;113-118.
57. Wiley J.L., Dewey M.A., Jefferson R.G., Winckler R.L., Bridgen D.T., Willoughby K.A., Martin B.R. Influence of phenylmethylsulfonyl fluoride on anandamide brain levels and pharmacological effects. Life Sci. 67:2000;1573-1583.
58. 1 receptor affinity. Pharmacology. 66:2002;89-99.
59. Willoughby K.A., Moore S.F., Martin B.R., Ellis E.F. The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther. 282:1997;243-247.
60. Zimmer A., Zimmer A.M., Hohmann A., Herkenham M., Bonner T. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. 96:1999;5780-5785.
61. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., Julius D., Hogestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:1999;452-457.